G. Vega-Hernández - Concepedia

Author

G. Vega-Hernández

Also Known As

G Vega-Hernandez, G. Vega-Hernandez, G. Vega-Hernández, Gabriela Vega-Hernandez, Gabriela Vega-Hernández, Gabriela Vega‐Hernandez

Publications

286

Citations

H-Index

Concepts

All Affiliations

G. Vega-Hernández is an author at Novo Nordisk (United Kingdom).

G. Vega-Hernández

Publications

226

Citations

H-Index

Page 1

	Year	Citations
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del Andrea Lopez, Conor Daly, G. Vega-Hernández, Journal of Cystic Fibrosis	2023	126
Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom Michael Feher, G. Vega-Hernández, Emina Mocevic, Diabetes Therapy	2017	21
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes Michael Feher, John Brazier, Nicolaas C. Schaper, BMJ Open Diabetes Research & Care	2016	20
Evaluation of the long‐term cost‐effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the <scp>UK</scp> setting Barnaby Hunt, G. Vega-Hernández, William J. Valentine, Diabetes Obesity and Metabolism	2017	20
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK G. Vega-Hernández, Radek Wojcik, Max Schlueter Diabetes Therapy	2017	20
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain Pedro Mezquita‐Raya, Antonio Ramírez de Arellano, Nana Kragh, Diabetes Therapy	2017	19

Page 1